RPL29P22

Across TCGA pan-cancer cohorts, RPL29P22 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL29P22’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where RPL29P22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL29P22 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

PRAD and KICH are the cancer types where RPL29P22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL29P22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.056	.036	2	view →
KICH	Female	All	−0.054	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

RPL29P22–PRAD

Open the PRAD breakdown →